Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | KIF11 | P52732 | 8/20 | 0.37 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | CTSG | P08311 | 1/20 | 0.33 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8334313 | 0.81 | KIF11 (0.44) | KIF11CSNK1EALDH1A1 | |
| SCHEMBL13083002 | 0.80 | CSNK1E (0.42) | CNR2KIF11CSNK1EALDH1A1PRSS1 | |
| SCHEMBL31676108 | 0.76 | HSD17B10 (0.47) | CNR2KIF11 | |
| SCHEMBL18704762 | 0.73 | KIF11 (0.36) | CNR2KIF11CSNK1EALDH1A1PRSS1 | |
| SCHEMBL10418792 | 0.73 | CSNK1E (0.40) | KIF11CSNK1EALDH1A1 | |
| SCHEMBL25400196 | 0.72 | KIF11 (0.42) | KIF11 | |
| SCHEMBL3188902 | 0.71 | KIF11 (0.39) | CNR2KIF11 | |
| SCHEMBL31578689 | 0.71 | KIF11 (0.50) | KIF11 | |
| SCHEMBL134594 | 0.71 | HSD17B10 (0.51) | KIF11 | |
| SCHEMBL18599373 | 0.69 | KIF11 (0.57) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007086882-A2 | BIOLOGICAL POLYMER WITH DIFFERENTLY CHARGED PORTIONS | TECHNOLOGY INNOVATIONS, LLC (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007050135-A2 | PROCESS FOR TREATING A BIOLOGICAL ORGANISM | TECHNOLOGY INNOVATIONS, LLC (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20050249667-A1 | Process for treating a biological organism | TECHNOLOGY INNOVATIONS, LLC | 2005-11-10 | — | — | US | disclosed |
| US-20050215764-A1 | Biological polymer with differently charged portions | TECHNOLOGY INNOVATIONS, LLC | 2005-09-29 | — | — | US | disclosed |
| EP-0716604-B1 | THIOL-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS INC (US) | 2005-03-16 | — | — | EP | disclosed |
| US-6265558-B1 | COMPOUND OF LINKED NUCLEOSIDES HAVING THIOL GROUP ATTATCHED AT 5-PYRIMIDINE OR 2-, 6-, OR 8-PURINE POSITIONS; ATTACHMENT REPORTER MOLECULES, REPORTER ENZYMES, STEROIDS, LIPOPHILIC MOLECULES, PEPTIDES, PROTEINS AND OTHER GROUPS | ISIS PHARMACEUTICALS, INC. | 2001-07-24 | — | — | US | disclosed |
| US-6232463-B1 | CROSSLINKING OLIGONUCLEOTIDES CONTAINING PURINE ANALOGS HAVING REACTIVE SITES ON THE NUCLEOBASE AND ON A SUGAR MOIETY; ANTISENSE AGENTS | ISIS PHARMACEUTICALS, INC. | 2001-05-15 | — | — | US | disclosed |
| EP-0716604-A4 | THIOL-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS INC (US) | 2000-12-27 | — | — | EP | disclosed |
| US-6114513-A | MEDICAL DIAGNOSIS; TRANSFER ACROSS CELL MEMBRANES | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| EP-0804456-A4 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS INC (US) | 1999-05-19 | — | — | EP | disclosed |
| EP-0742790-A4 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS INC (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0804456-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5681941-A | GENETIC ENGINEERING; CROSSLINKING OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1997-10-28 | — | — | US | disclosed |
| US-5578718-A | Thiol-derivatized nucleosides | ISIS PHARMACEUTICALS, INC. (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0742790-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1996-11-20 | — | — | EP | disclosed |
| EP-0716604-A1 | THIOL-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1996-06-19 | — | — | EP | disclosed |
| WO-1996011205-A9 | PEPTIDE NUCLEIC ACID CONJUGATES | — | 1996-05-30 | — | — | WO | disclosed |
| WO-1996011205-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1996-04-18 | — | — | WO | disclosed |
| WO-1995021184-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-10 | — | — | WO | disclosed |
| WO-1995006474-A1 | THIOL-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215764-A1 | Biological polymer with differently charged portions | TUBB3, TUBB1, TUBB | CNR2 4807/4885KIF11 72/4885CSNK1E 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.